InvestorsHub Logo
Post# of 251544
Next 10
Followers 826
Posts 119439
Boards Moderated 15
Alias Born 09/05/2002

Re: ronpopeil post# 193731

Saturday, 07/25/2015 6:22:09 PM

Saturday, July 25, 2015 6:22:09 PM

Post# of 251544
TEVA seeking to acquire AGN’s generic-drug business (i.e. the former Watson/Actavis) for ~$45B, according to sources:

If the above deal is consummated, TEVA would no longer pursue its hostile offer for MYL.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.